Inhibition of allergic reactions by cromoglycate and by a new antiallergy drug U-42,585E. II. Activity in primates against aerosolized Ascaris suum antigen.
Immediate type hypersensitivity to Ascaris antigen in Rhesus reactor monkeys was used to assess the pharmacologic profile of cromolyn Na (DSCG) and a new inhibitor of IgE-mediated lung function changes (U-42,585E). Two parameters used to measure lung function, respiratory rate increase and tidal volume decrease, were significantly altered in a dose-related fashion by U-42,585E when the latter was administered either by the intravenous, intrabronchial, or the oral route. Oral activity of U-42,585E was demonstrated with doses as low as 5 mg/kg in Ascaris reactor primates.
D000281:Administration, Intranasal; D000818:Animals; D000941:Antigens; D001200:Ascaris / Q000276:immunology*; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D000882:Haplorhini; D006967:Hypersensitivity / Q000517:prevention & control*; D012129:Respiratory Function Tests; D013997:Time Factors
D000941:Antigens; D004205:Cromolyn Sodium